Dietary Fibre and Psyllium
Fibre and psyllium husks change the gut microbiome, blood lipids and blood sugar; weight and digestion improve only in part.
We evaluated 234 human studies on Dietary Fibre and Psyllium, including 186 randomised controlled trials and 42 meta-analyses or systematic reviews; the controlled studies include 14,547 participants in total. As of 4 October 2026.
1. What Is Dietary Fibre and Psyllium? Occurrence, Origin and Forms
Dietary fibre is the part of plant foods that the human digestive tract does not break down. Psyllium husk is the outer layer of the seeds of Plantago ovata, a species in the plantain family; it swells strongly in water and forms a gel-like mass. Both are commonly used to support digestion and are added to foods.
Psyllium husk occurs in the seeds of Plantago ovata and is the swelling part of those seeds. Dietary fibre occurs in all plant foods, particularly in whole grains, legumes, vegetables, fruit, nuts and seeds.
The husks are obtained by separating the seeds of Plantago ovata from their coat and then milling the husks; the husks can also be used whole. Studies examine whole and milled husks, granules, powders stirred into liquid and foods fortified with them; for dietary fibre generally, isolated fibre powders and fibre-rich foods are also examined.
Forms and Preparations Studied
- Psyllium husk, whole or milled
- Whole psyllium seed with its coat
- Psyllium granules and powders stirred into liquid
- Foods and beverages fortified with psyllium husk
- Fibre-rich plant foods such as whole grains, legumes, vegetables and fruit
- Isolated fibre powders such as inulin or resistant starch
Not covered on this page:
- Probiotics, that is living microorganisms; they are not dietary fibre.
- Digestive enzymes such as lactase; they are proteins and not dietary fibre.
- Synthetic bulking and laxative agents; they do not come from plant foods.
2. What Does Dietary Fibre and Psyllium Do? Results by Area
| Area | Result in controlled studies | Strength of evidence | Studies | Participants |
|---|---|---|---|---|
| Gut Microbiome | mostly improved | high | 3 meta-analyses · 66 controlled · 2 other | 5,196 |
| Blood Lipids and Cholesterol | mostly improved | high | 10 meta-analyses · 46 controlled · 3 other | 4,100 |
| Blood Glucose and Insulin | mostly improved | high | 5 meta-analyses · 50 controlled · 8 other | 4,069 |
| Satiety and Body Weight | mixed | high | 8 meta-analyses · 41 controlled · 3 other | 2,128 |
| Irritable Bowel Syndrome and Digestive Complaints | mixed | high | 1 meta-analyses · 40 controlled · 5 other | 2,970 |
| Bowel Function and Stool Habits | mixed | high | 1 meta-analyses · 32 controlled · 5 other | 2,356 |
| Tolerance and Adverse Effects | mixed | low | 0 meta-analyses · 13 controlled · 19 other | 1,417 |
| Other investigations | mixed | high | 10 meta-analyses · 99 controlled · 11 other | 8,161 |
How to read the table: counted are human studies whose results concern the area. “High” means at least one meta-analysis and two controlled studies showing improvement, or at least three controlled studies of which three quarters show improvement, with at least 300 participants in total. “Moderate” means at least two controlled studies showing improvement, as a majority, or one meta-analysis alongside controlled studies. “Low” means one controlled study showing improvement. Where an area has no controlled study, the strength of evidence is at most “low” (result “reviews only” or “observational data only”). Everything else is “unclear”. A study counts as showing improvement when at least half of its outcomes in this area improved. Reviews of combination products do not count as meta-analyses; results that only describe side effects or shares of users do not count as an effect. The same study is counted only once.
3. What the Studies Show in Detail
Dietary Fibre and Psyllium and Gut Microbiome: Human Studies
Several controlled studies showed that fibre changes the gut microbiome. The frequency of individual bacterial groups shifted, for example towards more bifidobacteria, Parabacteroides, Lachnospira or Faecalibacterium 6983100112. Short-chain fatty acids increased with resistant starch, short-chain fructo-oligosaccharides and inulin 100108210; other studies found more bacteria that form such fatty acids 76105200. Microbial functions and metabolic products in the stool also changed 133139197204217. The composition of the gut flora also changed with inulin-type fructans and resistant starch 147204. This contrasts with results showing no difference: almonds changed neither the gut flora nor short-chain fatty acids in adults with anxiety or depressive symptoms 87. The findings come predominantly from isolated fibre powders such as inulin, resistant starch and fructo-oligosaccharides, as well as from fibre-rich foods such as oat bran. There are few microbiome studies on psyllium husk itself: in women with constipation, it changed the gut flora compared with placebo 230, but not in children with irritable bowel syndrome 77. The strength of evidence is high, but the studies are mostly small and short. Mixed preparations with probiotics or other additives do not allow conclusions about the individual fibre 202745.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 20 Chalif et al. 2026 | systematic review · 663 participants | Probiotic, prebiotic, or dietary fiber supplementation (heterogeneous formulations); vs. Control/placebo in included RCTs | Gut permeability and microbial composition: unclear |
| 27 Wang et al. 2026 | systematic review · 320 participants | synbiotics and low-protein high-fiber diet; vs. pooled analysis of 3 cross-sectional and 1 RCT study | SCFA-producing bacteria in CKD: worsened (P < 0.001) |
| 31 Xi et al. 2025 | meta-analysis · 187 participants | Dietary fiber supplements (form not reported); vs. Control without fiber supplementation | Fecal bifidobacteria concentration: improved (SMD = 5.142, 95% CI [3.716, 6.568], p = 0.000) |
| 40 Ribeiro et al. 2024 | systematic review | various prebiotics, mostly inulin-type fructans; 1 to 36 weeks; vs. randomized controlled trials | Bifidobacterium genus in gut microbiome: improved |
| 41 Ojo et al. 2021 | meta-analysis | Dietary fibre, form not specified; vs. Control group | Relative abundance of Bifidobacterium: improved (0.73 (95% CI: 0.57, 0.89)) |
| 43 Song et al. 2025 | randomised controlled · 802 participants | dietary fiber intervention, form not specified; 6 months; vs. usual care with patient education and dietary recommendations | microbiome-based clinical decision score (LightGBM): unclear |
| 45 Zhang et al. 2025 | randomised controlled · 478 participants | Probiotic and dietary fibre fermented milk (PFM); From first trimester until OGTT; vs. Intensive dietary and lifestyle (IDL) and standard care (SC) | Acidovorax abundance negatively associated with OGTT 0h glucose: unclear (p < 0.05) |
| 56 Lai et al. 2023 | randomised controlled · 250 participants | A polydextrose; B psyllium husk; C wheat bran+psyllium husk; D probiotics; placebo maltodextrin; 4 weeks; vs. placebo (maltodextrin), double-blinded randomized | Bifidobacterium abundance, group A vs placebo: improved (higher Bifidobacterium abundance than placebo at week 2 and 4); Anaerostipes trend, groups B and C: improved (increasing trends in groups B and C, associated with BMF increase) |
Further studies in this area: 57 62 63 65 66 67 69 72 76 77 82 83 85 87 88 96 99 100 101 102 103 104 105 108 110 112 121 124 125 126 129 133 137 138 139 140 147 148 152 156 157 158 160 167 173 174 178 179 186 187 192 193 197 200 204 206 208 209 210 213 217 229 230
Dietary Fibre and Psyllium, Blood Lipids and Cholesterol: Human Studies
For blood lipids and cholesterol, several controlled studies and meta-analyses showed improvements: in several studies psyllium husks lowered LDL cholesterol 7234253151. In a meta-analysis, oats and isolated beta-glucan lowered total and LDL cholesterol 11. In a meta-analysis, inulin-type fructans lowered LDL cholesterol and triglycerides 6, as did low-dose arabinoxylan with regular intake 206, and alpha-cyclodextrin reduced small LDL particles 98. A meta-analysis on fibre supplements, a study with a beta-glucan tablet and one with psyllium husks found no difference in LDL cholesterol 1855144. Triglycerides remained unchanged with psyllium husks in several studies 753151, HDL cholesterol remained the same 753 or fell slightly 151; sago starch changed no blood lipid value in type 2 diabetes 78. The findings are based on 46 controlled studies and 10 meta-analyses with around 4100 participants, predominantly on psyllium husks and oat beta-glucan; mixed preparations with further additives do not allow any statement about the individual fibre, and much remains open regarding dose, duration and long-term benefit.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 5 Juhász et al. 2023 | meta-analysis · 2,685 participants | Soluble dietary fibers, including galactomannans and psyllium; vs. Another fiber type or no fiber | Triglycerides: improved (SUCRA: 82.77%); LDL cholesterol: improved (SUCRA: 86.56%); Cholesterol: improved (SUCRA: 84.59%) |
| 6 Talukdar et al. 2024 | meta-analysis · 2,518 participants | Inulin-type fructans (ITF) supplementation; at least 2 weeks; vs. placebo, control, foods, or diets | LDL cholesterol: improved (MD -0.14 mmol/L, 95% CI: -0.24, -0.05); triglycerides: improved (MD -0.06 mmol/L, 95% CI: -0.12, -0.01); other cardiovascular disease risk factors: no difference (little to no significant effect) |
| 7 Gholami et al. 2025 | meta-analysis · 2,049 participants | Psyllium supplementation; dose-response analysis, exact amounts not reported; duration-response analysis, exact duration not reported; vs. control groups of included RCTs | total cholesterol: improved (Weighted Mean Differences: -9.05; 95% Confidence Intervals: -13.71, -4.40; p-value < 0.05); LDL cholesterol: improved (Weighted Mean Differences: -8.55; 95% Confidence Intervals: -12.92, -4.19; p < 0.001); triglycerides: no difference (Weighted Mean Differences: -5.29; 95% Confidence Intervals: -12.14, 1.54; p-value > 0.05) |
| 8 Xiang et al. 2025 | meta-analysis · 1,804 participants | Dietary fiber supplementation of different specificities; 1.5 to 40 g/day; 3 to 16 weeks; vs. Placebo, without energy restriction | LDL cholesterol (intermediate specificity): worsened (9.03-mg/dL increase in LDL cholesterol) |
| 10 Hartley et al. 2016 | systematic review · 1,513 participants | Dietary fibre from various sources, supplements or fibre-rich foods; mostly ≤ 12 weeks; vs. no intervention or minimal intervention | Total cholesterol: improved (mean difference -0.23 mmol/L, 95% CI -0.40 to -0.06); LDL cholesterol: improved (mean difference -0.14 mmol/L, 95% CI -0.22 to -0.06); Triglycerides: no difference (mean difference 0.00 mmol/L, 95% CI -0.04 to 0.05) |
| 11 de et al. 2023 | meta-analysis · 1,494 participants | Oats or isolated beta-glucan; at least two weeks; vs. placebo or control group | Total cholesterol (oats): improved (-0.61, 95%CI: -0.84;-0.39, p < 0.00001); Total cholesterol (oats, second analysis): improved (-0.70, 95%CI: -1.07;-0.34, p = 0.0002); LDL cholesterol (oats): improved (-0.51, 95%CI: -0.71;-0.31, p < 0.00001) |
| 14 Jiang et al. 2025 | meta-analysis · 1,140 participants | Intrinsic arabinoxylan-rich foods or isolated arabinoxylans/AXOS; vs. Control in randomized controlled trials | Total cholesterol (isolated AXOS): improved (MD: -0.14; 95 % CI: -0.27, -0.01; p = 0.03) |
| 18 Ranneh et al. 2026 | meta-analysis · 773 participants | Dietary fibre supplementation, form not specified; vs. Control group without fibre supplementation | HDL: no difference; LDL: no difference |
Further studies in this area: 21 23 34 41 42 43 49 50 53 55 70 73 78 79 80 84 90 91 98 107 112 114 116 118 119 120 127 131 132 135 136 142 143 144 150 151 155 163 164 170 174 181 182 185 201 206 215 221 222 225 226
Dietary Fibre and Psyllium, Blood Glucose and Insulin: Human Studies
In meta-analyses, psyllium husks lowered fasting blood sugar and HbA1c more than the control 1623, in one of them also insulin resistance 16. In meta-analyses, isolated fibre supplements in overweight lowered fasting insulin and insulin resistance more than the control 812, in a subgroup also HbA1c 8. In healthy people, alpha-cyclodextrin slightly lowered fasting blood sugar and insulin resistance compared with placebo 98. In healthy people, oat products dampened the rise in blood sugar after a meal more than white rice 203; a fibre-rich cereal supplement in type 2 diabetes with fatty liver lowered HbA1c and fasting blood sugar more than the control 211. In type 2 diabetes, biscuits with psyllium husks lowered HbA1c and fasting blood sugar more than placebo biscuits 131, psyllium husks added to a moderately carbohydrate-containing diet lowered fasting insulin 162. A meta-analysis on psyllium husks 16 and a study with sago starch in type 2 diabetes, which also did not lower blood sugar and HbA1c, found no difference in fasting insulin 78. In overweight pregnant women, a fibre powder lowered the frequency of gestational diabetes compared with the control 84, in a second study it did not 83. The robustness is high, but the results apply in each case to the form and preparation studied — whole or ground husks, granules, stirred powder or enriched foods — and cannot be transferred between isolated powders and fibre-rich foods. Mixed preparations of several fibre types do not allow any statement about the individual substance 2129.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 2 Colak et al. 2025 | meta-analysis · 3,420 participants | Dietary fiber supplementation as single isolated fibers, fiber mixtures, or fiber-rich whole foods; 1 to 12 months; vs. Placebo | Fasting glucose: improved (-0.07 mmol/L (95 % CI: -0.12, -0.02; P = 0.0005; I2 = 54 %)); Fasting insulin: improved (-5.89 pmol/L (95 % CI -9.18, -2.60, P = 0.0004; I2 = 89 %)); HOMA-IR: improved (-0.38 (95 % CI: -0.68, -0.08; P < 0.00001; I2 = 94 %)) |
| 4 Oliveira et al. 2025 | systematic review · 2,935 participants | Mediterranean diet high in fiber, MUFA and phenolics; at least 4 weeks; vs. usual diet or control | serum advanced glycation end product (AGE) concentrations: improved; skin autofluorescence levels: improved; gene expression of RAGE, AGER1 and glyoxalase I: improved |
| 5 Juhász et al. 2023 | meta-analysis · 2,685 participants | Soluble dietary fibers, including galactomannans and psyllium; vs. Another fiber type or no fiber | HbA1c: improved (SUCRA: 92.33%); Fasting blood glucose: improved (SUCRA: 85.92%); Fasting insulin: improved (SUCRA: 73.45%) |
| 8 Xiang et al. 2025 | meta-analysis · 1,804 participants | Dietary fiber supplementation of different specificities; 1.5 to 40 g/day; 3 to 16 weeks; vs. Placebo, without energy restriction | HbA1c: improved (reduced glycated hemoglobin (HbA1c) by 0.13%); Fasting insulin: improved (fasting insulin by 0.82 μIU/mL); HOMA-IR: improved (homeostatic model assessment of insulin resistance (HOMA-IR) by 0.33) |
| 12 Huwiler et al. 2022 | meta-analysis · 1,428 participants | Isolated soluble dietary fibre supplements; at least 12 weeks; vs. Control group | Fasting blood insulin: improved; HOMA-IR: improved |
| 14 Jiang et al. 2025 | meta-analysis · 1,140 participants | Intrinsic arabinoxylan-rich foods or isolated arabinoxylans/AXOS; vs. Control in randomized controlled trials | Fasting blood glucose: improved (SMD: -0.44; 95 % CI: -0.75, -0.13; p = 0.005); Fasting blood glucose in overweight/obesity: improved (SMD: -0.25; 95 % CI: -0.48, -0.03; p = 0.03); Fasting blood glucose (isolated AXOS): improved (SMD: -0.19; 95 % CI: -0.36, -0.02; p = 0.03) |
| 16 Gholami et al. 2024 | meta-analysis · 962 participants | Psyllium; Subgroups: less and more than 10 g/day; Subgroups: less than 50 days and longer; vs. Placebo | Fasting blood sugar: improved (WMD: -6.89; 95% CI: -10.62, -3.16; p < .001); HbA1c: improved (WMD: -0.75; 95% CI: -1.21, -0.29; p < .001); HOMA IR: improved (WMD: -1.17; 95% CI: -2.11, -0.23; p < .05) |
| 21 Hebbar et al. 2026 | systematic review · 641 participants | Dietary fiber of various types and sources (whole grains, legumes, flaxseed, composite flour); 5-50 g/day; 1 to 6 months; vs. randomized controlled trials, control groups not further described | Insulin resistance (HOMA-IR and related indices): improved (significantly improved); Fasting glucose: improved (notable improvements); HbA1c: improved (notable improvements) |
Further studies in this area: 23 28 29 32 33 43 45 49 62 67 68 73 78 79 83 84 85 91 94 98 105 108 112 113 114 116 119 123 127 131 135 137 142 150 159 162 165 167 172 175 181 185 189 190 194 196 198 199 201 202 203 205 211 214 215
Dietary Fibre and Psyllium, Satiety and Body Weight: Human Studies
For satiety and body weight, a mixed picture emerges. Several meta-analyses found an improvement in body weight and BMI from isolated soluble fibre powders, including inulin-type fructans from chicory root 681213. Psyllium husk also improved weight, BMI and waist circumference in a meta-analysis 26. A meta-analysis with chicory inulin-type fructans found an improvement in body composition 13, a randomised controlled trial with short-chain fructo-oligosaccharides did likewise 108, and one randomised controlled trial each with konjac glucomannan and with oligofructose-enriched inulin found a more favourable fat distribution 155209. These stand in contrast to findings with no difference: meta-analyses on psyllium husk in diabetes and on quinoa found no difference in weight and BMI 2328, and short-chain fructo-oligosaccharides none in body weight 108. The strength of evidence is high, but the results apply only to the form and preparation studied in each case; isolated powders, psyllium husk and enriched foods are not interchangeable. Mixed preparations of several fibres or with probiotics do not allow any statement about the individual substance 2174.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 6 Talukdar et al. 2024 | meta-analysis · 2,518 participants | Inulin-type fructans (ITF) supplementation; at least 2 weeks; vs. placebo, control, foods, or diets | body weight: improved (MD -0.97 kg, 95% CI: -1.28, -0.66) |
| 8 Xiang et al. 2025 | meta-analysis · 1,804 participants | Dietary fiber supplementation of different specificities; 1.5 to 40 g/day; 3 to 16 weeks; vs. Placebo, without energy restriction | Body weight (intermediate specificity): improved (2.85-kg decrease in body weight) |
| 12 Huwiler et al. 2022 | meta-analysis · 1,428 participants | Isolated soluble dietary fibre supplements; at least 12 weeks; vs. Control group | Body weight: improved (MD -1.25 kg, 95% CI -2.24, -0.25); BMI: improved; Waist circumference: improved |
| 13 Reimer et al. 2024 | meta-analysis · 1,184 participants | Chicory inulin-type fructans (ITF); Subgroup analysis for >8 weeks; vs. Placebo | Body weight: improved (MD: -0.97 kg; 95% CI: -1.34, -0.59); Body mass index: improved (MD: -0.39 kg/m2; 95% CI: -0.57, -0.20); Fat mass: improved (MD: -0.37 kg; 95% CI: -0.61, -0.13) |
| 15 de et al. 2026 | systematic review · 1,085 participants | Dietary fibers categorized by structure (dextrins, β-glucans, mannans, others); mostly acute interventions (71%); vs. control groups of included RCTs | satiety when GLP-1 increased: no difference (OR = 2.95, 95% CI: 0.87-9.98); satiety with dextrins: improved (5 positive studies); satiety with β-glucans: improved |
| 21 Hebbar et al. 2026 | systematic review · 641 participants | Dietary fiber of various types and sources (whole grains, legumes, flaxseed, composite flour); 5-50 g/day; 1 to 6 months; vs. randomized controlled trials, control groups not further described | Body weight: improved (notable improvements) |
| 23 Xiao et al. 2020 | meta-analysis · 395 participants | Psyllium; vs. Control (placebo/usual care) | Weight: no difference; Body mass index: no difference |
| 26 Gibb et al. 2023 | meta-analysis · 354 participants | Psyllium (psyllium husk), gel-forming fiber; mean dose 10.8 g/day, just before meals; mean duration 4.8 months; vs. control groups of included randomized trials | body weight: improved (MD = -2.1 kg [95% CI: -2.6 to -1.6]; p < .001); body mass index: improved (MD = -0.8 kg/m 2 [95% CI: -1.0 to -0.6]; p < .001); waist circumference: improved (MD = -2.2 cm [95% CI: -2.9 to -1.4]; p < .001) |
Further studies in this area: 28 29 41 45 65 74 78 83 84 90 94 108 112 114 118 126 131 132 137 142 150 155 159 162 163 167 171 172 174 181 189 190 194 195 199 202 205 206 209 211 213 214 221 228
Dietary Fibre and Psyllium, Irritable Bowel Syndrome and Digestive Complaints: Human Studies
Psyllium husk reduced the severity of irritable bowel syndrome more than placebo, in adults in general practices 54 as well as in children 219; in children the number of pain episodes also fell 77. In children with functional abdominal pain, psyllium husk relieved the pain and improved quality of life more than placebo 75; in adults with irritable bowel syndrome, quality of life did not differ from placebo 54. In chronic constipation, bloating improved with kiwis, but not with psyllium husk 95; inulin relieved abdominal complaints in functional constipation more than placebo 160. A randomised controlled trial with psyllium husk in addition to a proton pump inhibitor showed better symptom resolution in laryngopharyngeal reflux 44. A meta-analysis on inflammatory bowel diseases reports better remission rates in ulcerative colitis with certain fibres, but no difference for Plantago ovata in maintaining remission 35. The strength of evidence is overall high, but the form matters: in the study from general practices, bran did not reduce severity, and in the bran group the most participants dropped out because of worsened complaints 54. It remains open which preparation and dose work best for which complaints; mixed preparations with probiotics or laxatives do not allow conclusions about individual fibres.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Xu et al. 2025 | meta-analysis · 3,005 participants | Non-pharmacological interventions incl. dietary fiber; partly >4 weeks; vs. conventional treatment | Symptom score (eight indicators): improved (p < 0.05) |
| 20 Chalif et al. 2026 | systematic review · 663 participants | Probiotic, prebiotic, or dietary fiber supplementation (heterogeneous formulations); vs. Control/placebo in included RCTs | Postoperative bowel recovery and complications: improved |
| 24 Petticrew et al. 1997 | systematic review · 367 participants | laxatives of bulk, osmotic, stimulant and faecal softener classes, including psyllium; vs. single agent versus placebo and one laxative versus another | abdominal pain: unclear |
| 35 Limketkai et al. 2025 | meta-analysis | Prebiotics including Plantago ovata, inulin, FOS, lactulose, oat bran; vs. Placebo or lower-dose control | Clinical remission in ulcerative colitis (induction): improved (relative risk, 2.75, 95% confidence interval, 1.05-7.20); Clinical remission in ulcerative colitis (induction), OF-IN and lactulose: no difference; Maintenance of remission in ulcerative colitis, germinated barley foodstuff: improved (relative risk, 0.40; 95% confidence interval, 0.15-1.03) |
| 36 Ashoorion et al. 2025 | systematic review | Mediterranean diet, rich in fibers; vs. high vs. low adherence to Mediterranean diet | likelihood of functional dyspepsia: improved (AR:151 fewer, 95%CI: 74 to 203 fewer in 1,000) |
| 40 Ribeiro et al. 2024 | systematic review | various prebiotics, mostly inulin-type fructans; 1 to 36 weeks; vs. randomized controlled trials | inflammatory conditions overall: improved |
| 44 Rana et al. 2025 | randomised controlled · 505 participants | psyllium husk as adjunct to PPI; 16 weeks; vs. PPI monotherapy and PPI plus prokinetics | symptom resolution rate: improved (82%); mean RSI reduction: improved (9.70 ± 1.50); mean RFS reduction: improved (5.00 ± 0.95) |
| 47 Peng et al. 2019 | randomised controlled · 412 participants | high-fiber DASH diet vs. low-fiber Western diet; 32 g fiber/d (DASH) vs. 11 g/d (control); sodium 50, 100, 150 mmol/d; three 30-day periods with 5-day breaks between; vs. low-fiber Western control diet; three sodium levels in crossover | risk of bloating on high-fiber DASH diet: worsened (risk ratio = 1.41; 95% confidence interval: 1.22-1.64; P < 0.001); risk of bloating with high sodium intake: worsened (risk ratio = 1.27; 95% confidence interval: 1.06-1.52; P = 0.01) |
Further studies in this area: 54 71 75 77 87 89 93 95 96 102 103 109 113 114 122 126 128 129 134 140 141 146 148 152 160 166 168 178 179 180 187 191 206 213 216 218 219 224
Dietary Fibre and Psyllium, Bowel Function and Stool Habits: Human Studies
Psyllium husk reduced the number of episodes in faecal incontinence more than placebo 58 and worked similarly to loperamide 93. In type 2 diabetes with chronic constipation, biscuits with psyllium husk relieved the constipation complaints 131, and inulin increased stool frequency in functional constipation more than placebo 160. A meta-analysis in older people with constipation found no difference in stool frequency, but less use of laxatives and enemas 31. In healthy people, fibre-rich foods improved gut-related quality of life 76. It remains open which preparation form and dose work most reliably in which patient group; the studies were partly small and short.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Xu et al. 2025 | meta-analysis · 3,005 participants | Non-pharmacological interventions incl. dietary fiber; partly >4 weeks; vs. conventional treatment | Efficacy of constipation treatment: improved (RR = 1.15, 95% CI = 1.09 to 1.21, p < 0.00001); Bristol stool scale: improved (SMD = 0.87, 95% CI = 0.14-1.60, p = 0.02); CSBM scale: improved (SMD = 0.44, 95% CI = -0.52-0.12, p = 0.03) |
| 20 Chalif et al. 2026 | systematic review · 663 participants | Probiotic, prebiotic, or dietary fiber supplementation (heterogeneous formulations); vs. Control/placebo in included RCTs | Incidence and severity of radiation-induced diarrhea: improved (P<.05); Stool consistency: improved; Antidiarrheal use: improved (P<.05) |
| 24 Petticrew et al. 1997 | systematic review · 367 participants | laxatives of bulk, osmotic, stimulant and faecal softener classes, including psyllium; vs. single agent versus placebo and one laxative versus another | bowel movements per week, symptom improvement, stool consistency: unclear |
| 31 Xi et al. 2025 | meta-analysis · 187 participants | Dietary fiber supplements (form not reported); vs. Control without fiber supplementation | Stool frequency: no difference (SMD = 0.25, 95% CI [-0.488, 0.988], p = 0.507); Frequency of laxative or enema use: improved (SMD = -1.224, 95% CI [-1.786, -0.662], p = 0.000) |
| 49 Shen et al. 2024 | randomised controlled · 376 participants | High-fiber diet plus daily soluble fiber supplement; until delivery; vs. intervention group vs. control (standard care) | need for constipation medication: improved |
| 56 Lai et al. 2023 | randomised controlled · 250 participants | A polydextrose; B psyllium husk; C wheat bran+psyllium husk; D probiotics; placebo maltodextrin; 4 weeks; vs. placebo (maltodextrin), double-blinded randomized | bowel movement frequency (BMF): no difference (No time-by-group effect was observed for bowel movement frequency (BMF)); Bristol stool scale score (BSS): improved (mean increases of 0.95-1.05 in group A to D (all P < 0.05)); Bristol stool scale score (BSS), placebo: no difference (P = 0.170) |
| 58 Bliss et al. 2014 | randomised controlled · 189 participants | Psyllium vs. carboxymethylcellulose, gum arabic, placebo; 16 g total fiber/day; 32 days after 14-day baseline; vs. Placebo and other fiber types | Fecal incontinence episodes per week: improved (2.5 for Psyllium); Fecal incontinence episodes per week: worsened (6.2 for CMC) |
| 69 Perreau et al. 2026 | randomised controlled · 124 participants | Resistant dextrin (NUTRIOSE® soluble fiber) vs. placebo (maltodextrin); 15 g/day; 4 weeks; vs. Placebo (maltodextrin) | Stool consistency and frequency: no difference (p > 0.05) |
Further studies in this area: 76 77 81 86 87 89 93 95 106 111 113 122 130 131 134 137 141 146 160 168 179 180 183 216 218 223 227 230 232 233
Dietary Fibre and Psyllium, Tolerance and Adverse Effects: Human Studies
The tolerability of fibres and psyllium husk was examined in 13 controlled studies with a total of 1417 participants, but the results are mixed and the strength of evidence is low. Individual studies reported abdominal distension, bloating and discomfort with psyllium husk 144 or more side effects than with kiwis 95. With beta-glucan tablets, one of three dose groups had gastrointestinal complaints more often than placebo 55, and a fibre-rich DASH diet increased the risk of bloating 47. With mixed preparations of several fibres or with further additives such as probiotics, PPI or colestipol, the effect of the individual substance cannot be derived 335. It remains open how tolerability behaves with longer administration and with different dosages, since many studies were short and small.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 3 Xu et al. 2025 | meta-analysis · 3,005 participants | Non-pharmacological interventions incl. dietary fiber; partly >4 weeks; vs. conventional treatment | Adverse events (RR = 0.35, 95% CI = 0.16 to 0.74, p = 0.006) |
| 10 Hartley et al. 2016 | systematic review · 1,513 participants | Dietary fibre from various sources, supplements or fibre-rich foods; mostly ≤ 12 weeks; vs. no intervention or minimal intervention | Adverse events |
| 20 Chalif et al. 2026 | systematic review · 663 participants | Probiotic, prebiotic, or dietary fiber supplementation (heterogeneous formulations); vs. Control/placebo in included RCTs | Adverse events |
| 35 Limketkai et al. 2025 | meta-analysis | Prebiotics including Plantago ovata, inulin, FOS, lactulose, oat bran; vs. Placebo or lower-dose control | Adverse events |
| 44 Rana et al. 2025 | randomised controlled · 505 participants | psyllium husk as adjunct to PPI; 16 weeks; vs. PPI monotherapy and PPI plus prokinetics | adherence rate: improved (85%) |
| 49 Shen et al. 2024 | randomised controlled · 376 participants | High-fiber diet plus daily soluble fiber supplement; until delivery; vs. intervention group vs. control (standard care) | safety of long-term soluble fiber supplementation |
| 50 MacMahon et al. 1998 | randomised controlled · 340 participants | Ispaghula husk; 7.0 or 10.5 g/day; 12 weeks treatment, some further 12 weeks; 8-week diet period; vs. Placebo plus dietary advice | tolerability (well tolerated) |
| 54 Bijkerk et al. 2009 | randomised controlled · 275 participants | 10 g psyllium vs. 10 g bran vs. 10 g placebo (rice flour); 10 g daily; 12 weeks; vs. Placebo (rice flour) and bran (insoluble fibre) | Completion of the 3-month treatment period: unclear (Fifty four (64%) of the patients allocated to psyllium, 54 (56%) in the bran group, and 56 (60%) in the placebo group) |
Further studies in this area: 55 58 70 73 74 81 87 90 93 95 98 105 107 135 144 157 163 164 182 184 212 214 216 224
Dietary Fibre and Psyllium: Further Outcomes in Studies
Several controlled studies found improvements in inflammatory markers, for instance in IL-6 through psyllium husk in obese adolescents and in hs-CRP through inulin in women with polycystic ovary syndrome 8097. In a controlled study, Parkinson's symptoms improved with resistant starch 100. In chronic kidney disease, resistant starch lowered indoxyl sulfate and blood urea nitrogen in a meta-analysis 25. In a meta-analysis, psyllium husk lowered systolic blood pressure, more so with a higher baseline value 22; resistant starch lowered it slightly in women with metabolic risks, but increased body fat and triglycerides 174. A prebiotic fibre did not change lipopolysaccharide-binding protein overall in healthy young adults, but lowered it in a subgroup with an elevated baseline value 188. In type 2 diabetes with fatty liver, the fibrosis index FIB-4 fell with a fibre-rich cereal supplement 211. Inulin improved quality of life in functional constipation 160 and in rheumatoid arthritis lowered CRP, disease activity and the number of swollen joints more than the control 115. In women with migraine, inulin reduced the severity, duration and frequency of attacks as well as depressive symptoms more than placebo 92. Other studies with psyllium husk found no difference from the control in intestinal permeability 77 and quality of life 58. The robustness is overall high, but many studies were small, short and examined different forms, dosages and populations; mixed preparations do not allow conclusions about individual fibres.
| Study | Design · participants | Preparation · dose · duration · comparison | Result |
|---|---|---|---|
| 1 Shi et al. 2026 | meta-analysis · 10,262 participants | Blueberry combined with dietary fiber (one of 24 strategies); vs. Standard controls | Cesarean section rate in high-risk pregnant women: improved (RR = 0.30, 95% CI: 0.10, 0.90; SUCRA = 97.8%) |
| 8 Xiang et al. 2025 | meta-analysis · 1,804 participants | Dietary fiber supplementation of different specificities; 1.5 to 40 g/day; 3 to 16 weeks; vs. Placebo, without energy restriction | Systolic blood pressure (mixed subgroup): worsened (increase in systolic blood pressure by 3.85 mmHg) |
| 9 Nada et al. 2026 | systematic review · 1,615 participants | Mediterranean diet (plant-based, fiber-rich); vs. lower vs. higher MedDiet adherence or control | inflammatory markers (CRP): improved; disease activity: improved; quality of life: improved |
| 10 Hartley et al. 2016 | systematic review · 1,513 participants | Dietary fibre from various sources, supplements or fibre-rich foods; mostly ≤ 12 weeks; vs. no intervention or minimal intervention | Diastolic blood pressure: improved (mean difference -1.77 mmHg, 95% CI -2.61 to -0.92); Systolic blood pressure: unclear (mean difference -1.92 mmHg, 95% CI -4.02 to 0.19) |
| 14 Jiang et al. 2025 | meta-analysis · 1,140 participants | Intrinsic arabinoxylan-rich foods or isolated arabinoxylans/AXOS; vs. Control in randomized controlled trials | Systolic blood pressure: improved (MD: -2.86; 95 % CI: -5.45, -0.27; p = 0.03); Lymphocyte count (isolated AXOS): improved (MD: 3.52; 95 % CI: 0.75, 6.29; p = 0.01) |
| 15 de et al. 2026 | systematic review · 1,085 participants | Dietary fibers categorized by structure (dextrins, β-glucans, mannans, others); mostly acute interventions (71%); vs. control groups of included RCTs | GLP-1 secretion with dextrins: improved (4 positive studies); GLP-1 secretion with mannans: improved |
| 17 Gholami et al. 2024 | meta-analysis · 802 participants | Psyllium; dose-response analysis, exact amounts not reported; duration-response analysis, exact duration not reported; vs. control groups of included RCTs | Systolic blood pressure: improved (WMD: -2.24; 95% CI: -3.13, -1.35; p < .05); Diastolic blood pressure: no difference (WMD: 0.04; 95% CI: -0.52, 0.61; p > .05) |
| 18 Ranneh et al. 2026 | meta-analysis · 773 participants | Dietary fibre supplementation, form not specified; vs. Control group without fibre supplementation | Serum lipopolysaccharide: improved (p < 0.00001, I2 = 97%); TNF-α: improved (p < 0.02, I2 = 90%); IL-10: improved (p < 0.02, I2 = 85%) |
Further studies in this area: 19 22 25 27 29 30 37 38 39 41 43 46 48 51 52 56 57 58 59 60 61 62 64 66 67 68 69 71 76 77 79 80 82 83 84 85 87 88 90 92 93 97 99 100 101 102 103 104 106 109 110 113 114 115 116 117 118 119 120 121 123 124 126 127 129 133 136 138 140 142 143 145 146 147 149 150 153 154 155 158 160 161 166 169 171 174 176 177 179 184 185 186 187 188 190 194 197 202 205 206 207 209 211 213 215 220 222 224 225 231 232 233
4. How Is Dietary Fibre and Psyllium Dosed? Preparation, Dose and Duration in Studies
The studies tested psyllium husks as whole or ground husks, as granules and as a stirred powder, as well as foods enriched with psyllium husks 5053545895. In addition came isolated fibres such as inulin, resistant starch, beta-glucan and fructo-oligosaccharides 1162100108 as well as fibre-rich foods such as oats, avocado, almonds or a fibre-rich DASH diet 344787203. The forms and preparations tested are not interchangeable; the table shows the doses.
| Preparation or form | Dose | Duration | Study |
|---|---|---|---|
| dietary fiber intervention, form not specified | — | 6 months | 43 |
| psyllium husk as adjunct to PPI | — | 16 weeks | 44 |
| Probiotic and dietary fibre fermented milk (PFM) | — | From first trimester until OGTT | 45 |
| calcium-enriched permeate with inulin (CP-Inu) vs. CP, calcium carbonate, placebo | 800 mg calcium daily in 2 doses; inulin amount not reported; 20 µg vitamin D daily | 12 months | 46 |
| high-fiber DASH diet vs. low-fiber Western diet | 32 g fiber/d (DASH) vs. 11 g/d (control); sodium 50, 100, 150 mmol/d | three 30-day periods with 5-day breaks between | 47 |
| GOS/inulin prebiotic versus placebo (maltodextrin) | daily, amount not reported | from 20 weeks' gestation until delivery; follow-up to 1 year | 48 |
| High-fiber diet plus daily soluble fiber supplement | — | until delivery | 49 |
| Ispaghula husk | 7.0 or 10.5 g/day | 12 weeks treatment, some further 12 weeks; 8-week diet period | 50 |
| DASH diet or FV diet (fruit- and vegetable-rich) | — | 8 weeks of monitored feeding | 51 |
| Free medically tailored groceries high in dietary fibre | — | 12-week intervention, follow-up to 12 months | 52 |
| Foods containing psyllium seed husk (PSH) | 0, 3.4, 6.8, or 10.2 g PSH/d | 24 weeks | 53 |
| 10 g psyllium vs. 10 g bran vs. 10 g placebo (rice flour) | 10 g daily | 12 weeks | 54 |
| β-glucan tablet, high-medium molecular weight | 1.5, 3 or 6 g/day | 12 weeks | 55 |
| A polydextrose; B psyllium husk; C wheat bran+psyllium husk; D probiotics; placebo maltodextrin | — | 4 weeks | 56 |
| Prebiotic blend of inulin and oligofructose | — | 3 months | 57 |
5. Is Dietary Fibre and Psyllium Safe? Side Effects in Studies
Psyllium husks were well tolerated in a placebo-controlled study in people with elevated cholesterol 50; in faecal incontinence, constipation occurred less often with them than with loperamide 93. Other studies found no differences in intestinal complaints, intolerance or adverse events 588798. The evidence on tolerability is low, and little is known about longer-term use and different dosages.
| Study | Reported side effects |
|---|---|
| 3 Xu et al. 2025 | Adverse events less frequent than control (RR 0.35) |
| 7 Gholami et al. 2025 | not reported |
| 10 Hartley et al. 2016 | mostly mild to moderate gastrointestinal side-effects, more frequent in fibre groups |
| 17 Gholami et al. 2024 | not reported |
| 20 Chalif et al. 2026 | Adverse events infrequent, no major safety concerns identified |
| 22 Clark et al. 2020 | no reported side effects |
| 25 Zhang et al. 2024 | not reported in abstract |
| 27 Wang et al. 2026 | high-fiber diet safe in non-dialysis patients |
| 31 Xi et al. 2025 | Adverse events assessed, results not reported |
| 35 Limketkai et al. 2025 | Flatulence and bloating more common with OF-IN; otherwise similar to controls |
| 44 Rana et al. 2025 | favourable safety profile, no details reported |
| 46 Tetens et al. 2026 | not reported |
6. What Remains Open: Limits of the Evidence
- Many studies were small and short, so long-term effects on the microbiome, blood lipids and blood sugar remain open.
- Only few microbiome data are available on psyllium husks themselves; most microbiome findings come from isolated fibre powders.
- Results on isolated fibre powders cannot be transferred to fibre-rich foods and vice versa.
- Mixed preparations of several fibres or with probiotics, PPI or colestipol do not allow any statement about the individual fibre.
- It remains open which preparation form and dose works most reliably for which complaints and patient groups.
7. Bottom Line: What Is Established About Dietary Fibre and Psyllium
Fibre and psyllium husks are well-studied plant substances with predominantly favourable findings in humans. The findings apply in each case only to the form and preparation studied, and mixed preparations do not allow conclusions about individual fibres.
Frequently Asked Questions
How well has Dietary Fibre and Psyllium been studied in humans?
We evaluated 234 human studies on Dietary Fibre and Psyllium, including 186 randomised controlled trials and 42 meta-analyses or systematic reviews; the controlled studies include 14,547 participants in total. As of 4 October 2026.
Does Dietary Fibre and Psyllium help with gut Microbiome? What the studies show
Does Dietary Fibre and Psyllium help with blood Lipids and Cholesterol? What the studies show
Does Dietary Fibre and Psyllium help with blood Glucose and Insulin? What the studies show
Does Dietary Fibre and Psyllium help with satiety and Body Weight? What the studies show
Does Dietary Fibre and Psyllium help with irritable Bowel Syndrome and Digestive Complaints? What the studies show
Does Dietary Fibre and Psyllium help with bowel Function and Stool Habits? What the studies show
What are psyllium husks and how do they work?
What effects do studies in humans show on blood lipids and blood sugar?
In meta-analyses and controlled studies, psyllium husk lowered LDL cholesterol 723425053151, and in several cases also total cholesterol 742151. In meta-analyses, it also lowered fasting blood glucose and HbA1c 1623. However, individual studies found no difference for individual lipid values 185578144.
Do fibre and psyllium husks help with weight loss?
How does fibre affect the gut microbiome?
The findings come predominantly from isolated fibre powders such as inulin and resistant starch as well as from fibre-rich foods such as oat bran. On psyllium husks themselves there are few microbiome studies: in women with constipation they changed the gut flora compared with placebo 230, in children with irritable bowel syndrome they did not 77.
Sources
- 1Shi J, Chen K, Tang Y, Ren X, Zhang Y · 2026
- 2Colak H, Larik GNF, van Baak MA, Canfora EE · 2025
- 3Xu L, Leng Y, Dai P, Gao H, Chu Y, Chen X et al. · 2025
- 4Oliveira JS, da Silva JA, de Freitas BVM, Alfenas RCG, Bressan J · 2025
- 5Juhász AE, Greff D, Teutsch B, Gede N, Hegyi P, Horváth EM et al. · 2023
- 6Talukdar JR, Cooper M, Lyutvyn L, Zeraatkar D, Ali R, Berbrier R et al. · 2024
- 7
- 8
- 9Nada AH, Ghonaim MM, Awad A, Kanaan D, Abbas AN, Alfaki A et al. · 2026
- 10Hartley L, May MD, Loveman E, Colquitt JL, Rees K · 2016
- 11de Morais Junior AC, Schincaglia RM, Viana RB, Armet AM, Prado CM, Walter J et al. · 2023
- 12Huwiler VV, Schönenberger KA, Segesser von Brunegg A, Reber E, Mühlebach S, Stanga Z et al. · 2022
- 13
- 14Jiang S, Cai C, Deehan EC, Chen J, Feng C, Yang M et al. · 2025
- 15de Jong JCBC, Lentjes MGW, Pietersma KF, Pasman WJ, Wopereis S, Hoevenaars FPM · 2026
- 16
- 17
- 18Ranneh Y, Hamsho M, Fadel A, Al Raish S, Ali Ghazzawi H, Hoteit M et al. · 2026
- 19Wathanavasin W, Cheungpasitporn W, Thongprayoon C, Fülöp T · 2025
- 20Chalif J, Morton M, Haight P, Mehra Y, O'Malley D, Spakowicz D et al. · 2026
- 21Hebbar S, Umakanth S, Thimmappa L, Amrutha MS, Galbao J, Nayak SH · 2026
- 22Clark CCT, Salek M, Aghabagheri E, Jafarnejad S · 2020
- 23Xiao Z, Chen H, Zhang Y, Deng H, Wang K, Bhagavathula AS et al. · 2020
- 24Petticrew M, Watt I, Sheldon T · 1997
- 25Zhang Y, Hu XY, Yang SY, Hu YC, Duan K · 2024
- 26Gibb RD, Sloan KJ, McRorie JW · 2023
- 27
- 28Atefi M, Heidari Z, Shojaei M, Askari G, Kesharwani P, Bagherniya M et al. · 2024
- 29Stachowska E, Portincasa P, Jamioł-Milc D, Maciejewska-Markiewicz D, Skonieczna-Żydecka K · 2020
- 30
- 31Xi N, Yang X, Liu J, Yue H, Wang Z · 2025
- 32Fang JX, Huang F, Gu Q, Meng J, Zou HM, Han Y et al. · 2026
- 33Victoria-Montesinos D, González-Louzao R, Barcina-Pérez P, Mercader-Ros MT, Lucas-Abellán C, Daruich-González IB et al. · 2026
- 34Mostafazadeh P, Etesamnia S, Nasiraei-Moghadam M, Jahan-Mihan A, Haghighi A, Zendedel A et al. · 2026
- 35Limketkai BN, Godoy-Brewer G, Shah ND, Maas L, White J, Parian AM et al. · 2025
- 36Ashoorion V, Hosseinian SZ, Rezaei N, Hajihashemi P, Zare-Farashbandi E, Adibi P · 2025
- 37Benedicto-Toboso MI, Freire Salviano A, Miguel-Berges ML, Rueda-De Torre I, Moreno LA, Santaliestra-Pasías AM · 2025
- 38Mirzohreh ST, Sohrabnavi A, Panahi P, Nikniaz Z, Farhangi MA, Daneghian S et al. · 2025
- 39Aslam H, Lotfaliany M, So D, Berding K, Berk M, Rocks T et al. · 2024
- 40Ribeiro MC, Levi Y, Moraschini V, Messora MR, Furlaneto FAC · 2024
- 41
- 42Wei ZH, Wang H, Chen XY, Wang BS, Rong ZX, Wang BS et al. · 2009
- 43Song D, Feng G, Ma Y, Shi Y, Qian C, Wang C et al. · 2025
- 44Rana AK, Sharma R, Verma M, Singh AD, Mehrotra A · 2025
- 45Zhang L, Wang J, Zheng W, Yuan X, Liu C, Xin Y et al. · 2025
- 46Tetens I, Kisi SB, Parlesak A, Rasmussen SI, Cramon MØ, Petersen CF et al. · 2026
- 47Peng AW, Juraschek SP, Appel LJ, Miller ER, Mueller NT · 2019
- 48Barbarot S, Aubert H, Boivin M, Foureau A, Maruani A, Droitcourt C et al. · 2026
- 49Shen H, Chen D, Wang S, Jin Y, Cheng W · 2024
- 50MacMahon M, Carless J · 1998
- 51Juraschek SP, Yokose C, McCormick N, Miller ER, Appel LJ, Choi HK · 2021
- 52Hao Z, Peddie M, Ashton N, Anderson L, Wang NX, Reynolds A · 2025
- 53Davidson MH, Maki KC, Kong JC, Dugan LD, Torri SA, Hall HA et al. · 1998
- 54Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW · 2009
- 55Rioux-Labrecque V, Cossette M, Rufiange M, Bilodeau D, Guertin MC, Tardif JC · 2023
- 56Lai H, Li Y, He Y, Chen F, Mi B, Li J et al. · 2023
- 57Yang J, Hou L, Wang A, Shang L, Jia X, Xu R et al. · 2024
- 58Bliss DZ, Savik K, Jung HJ, Whitebird R, Lowry A, Sheng X · 2014
- 59Kabisch S, Montagna F, Honsek C, Kemper M, Gerbracht C, Arafat AM et al. · 2025
- 60Palacios C, Trak-Fellermeier MA, Hernandez J, Galvan R, Martinez-Motta P, Machi A et al. · 2026
- 61King DE, Mainous AG, Egan BM, Woolson RF, Geesey ME · 2008
- 62Panichsillaphakit E, Visuthranukul C, Chongpison Y, Chuaypen N, Kwanbunbumpen T, Uaariyapanichkul J et al. · 2025
- 63Andriyas T, Sriswasdi S, Tansawat R, Uaariyapanichkul J, Chomtho S, Visuthranukul C · 2025
- 64Kadim M, Hegar B, Bardosono S, Timan IS, Gunardi H, Prasetyo D et al. · 2020
- 65Aksornkitti V, Visuthranukul C, Leelahavanichkul A, Joyjinda Y, Sriswasdi S · 2025
- 66
- 67Li J, Liu F, Luo Y, Wijeyesekera A, Wang S, Chen X et al. · 2025
- 68Kabisch S, Meyer NMT, Honsek C, Kemper M, Gerbracht C, Arafat AM et al. · 2022
- 69Perreau C, Tomassi D, Capronnier O, Carton T, Thabuis C, Guérin-Deremaux L · 2026
- 70Spence JD, Huff MW, Heidenheim P, Viswanatha A, Munoz C, Lindsay R et al. · 1995
- 71COMPARATIVE EFFECTIVENESS OF CONSERVATIVE METHODS FOR ACCELERATING EPITHELIALIZATION IN ACUTE ANAL FISSURELukina V, Katibgadzhiev M, Solovyov S, Kovalenko P, Kuzmich V, Eremeeva M et al. · 2026
- 72
- 73Martino F, Puddu PE, Pannarale G, Colantoni C, Martino E, Niglio T et al. · 2013
- 74Pokushalov E, Ponomarenko A, Garcia C, Pak I, Shrainer E, Seryakova M et al. · 2024
- 75Kaur M, Poddar U, Srivastava A, Sarma MS, Mishra P · 2026
- 76Inoue R, Suzuki K, Takaoka M, Narumi M, Naito Y · 2025
- 77Shulman RJ, Hollister EB, Cain K, Czyzewski DI, Self MM, Weidler EM et al. · 2017
- 78King TL, Bugam SH, Khoo SY, Tan SH, Yeo JJP, Tan SSN et al. · 2025
- 79Mendivil EJ, Rivera-Iñiguez I, Arellano-Gómez LP, Martínez-López E, Hernández-Guerrero C, Sayago-Ayerdi SG et al. · 2025
- 80González AP, Flores-Ramírez A, Gutiérrez-Castro KP, Luévano-Contreras C, Gómez-Ojeda A, Sosa-Bustamante GP et al. · 2021
- 81Quitadamo P, Coccorullo P, Giannetti E, Romano C, Chiaro A, Campanozzi A et al. · 2012
- 82Li T, Lu Z, Peng W, Liu J, Yuan J, Zhu L et al. · 2026
- 83Zhang D, Sheng J, He P, Wang J, Zhou M, Sun Y et al. · 2026
- 84Zhang DY, Cheng DC, Cao YN, Su Y, Chen L, Liu WY et al. · 2022
- 85Iino C, Mikami K, Furusawa K, Sato S, Yoshida K, Yamaguchi T et al. · 2026
- 86Jamshidi MS, Malekpour H, Abdi S, Farhan F · 2022
- 87Sartori L, Argomaniz N, Farsi DN, Bajka B, Chrysostomou D, Marchesi JR et al. · 2026
- 88Petelina TI, Avdeeva KS, Valeeva LL, Bykova SG, Zueva EV, Dorodneva EF · 2025
- 89Maheshwari D, Hall CD, Jia X, Tangada A, Wu EK, Leung K et al. · 2022
- 90A study to assess the effect of dietary supplementation with soluble fibre (Minolest) on lipid levels in normal subjects with hypercholesterolaemiaTai ES, Fok AC, Chu R, Tan CE · 1999
- 91Dehzad MJ, Raja A, Moghdani Z, Sohrabi Z, Fararooei M, Famouri M et al. · 2025
- 92
- 93Markland AD, Burgio KL, Whitehead WE, Richter HE, Wilcox CM, Redden DT et al. · 2015
- 94Xiao J, Liu C, Shao T, Kang D, Tang H, Liu F et al. · 2026
- 95Chey SW, Chey WD, Jackson K, Eswaran S · 2021
- 96Valcheva R, Armstrong H, Kovic O, Bording-Jorgensen M, Veniamin S, Pérez-Muñoz ME et al. · 2022
- 97Ziaei R, Shahshahan Z, Ghasemi-Tehrani H, Heidari Z, Ghiasvand R · 2022
- 98Amar MJ, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT · 2016
- 99Fan J, le Gall G, Malcomson FC, Louca P, Beck L, Nelson A et al. · 2026
- 100Petrov VA, Schade S, Laczny CC, Hällqvist J, May P, Jäger C et al. · 2026
- 101Hegelmaier T, Duscha A, Desel C, Fuchs S, Shapira M, Amidror S et al. · 2025
- 102van den Belt M, Liu Z, Janssen Duijghuijsen L, Zoetendal EG, Witteman B, de Roos NM et al. · 2025
- 103
- 104Mannila E, Gómez-Gallego C, Muluh G, Nuotio P, Koistinen V, Erawijantari PP et al. · 2026
- 105Tamahane V, Shah N, Kajale N, Khadilkar A, Khadilkar V, Gondhalekar K et al. · 2026
- 106Honda M, Minato-Inokawa S, Matsuura K, Ito A, Nitta Y, Kimura D et al. · 2025
- 107Moreyra AE, Wilson AC, Koraym A · 2005
- 108Le Bourgot C, Capronnier O, Graf S, Carton T · 2025
- 109Qayyum S, Sultana A, Heyat MBB, Rahman K, Akhtar F, Haq AU et al. · 2023
- 110Zakis DR, Brandt BW, van der Waal SV, Keijser BJF, Crielaard W, van der Plas DWK et al. · 2024
- 111Psyllium fiber vs. placebo in early treatment after STARR for obstructed defecation: a randomized double-blind clinical trialGabrielli F, Macchini D, Guttadauro A, Frassani S, Bertolini A, Giussani C et al. · 2016
- 112Hu H, Tian Q, Wang L, Mu L, Zhou X, Liu B et al. · 2026
- 113Marcobal AM, Ng KM, Drexler RA, McConnell BR, Amicucci MJ · 2026
- 114Vaghef-Mehrabany E, Ranjbar F, Asghari-Jafarabadi M, Hosseinpour-Arjmand S, Ebrahimi-Mameghani M · 2021
- 115Tabatabaeyan A, Grigorian A, Salesi M, Fiezi A, Kafeshani M · 2025
- 116Teparak C, Uriyapongson J, Phoemsapthawee J, Tunkamnerdthai O, Aneknan P, Tong-Un T et al. · 2025
- 117
- 118Gill H, Lankatillake C, Zafiris E, Pillidge C · 2026
- 119Charoensriwattanakul K, Visuthranukul C, Pongchaidacha P, Tepaamorndech S, Suppavorasatit I, Chomtho S · 2026
- 120Wang J, Ma F, Wang PF, Hung CH, Wu KT, Liao LA et al. · 2026
- 121Jensen DEA, Thieleking R, Medawar E, Reinicke M, Rolle-Kampczyk U, von Bergen M et al. · 2026
- 122Di Minno A, Morone MV, Buccato DG, De Lellis LF, Ullah H, Cerqua A et al. · 2026
- 123Wang S, Gao H, Cai H, Liu L, Li Y, Gao M et al. · 2026
- 124Hogenelst K, Krone T, Eveleens Maarse B, Warnke I, Snabel J, van den Broek TJ et al. · 2025
- 125Hoevenaars FPM, Scheithauer TPM, Eveleens Maarse BC, de Oliveira IM, Warnke I, Sybesma W et al. · 2025
- 126Fortuna R, Wang W, Mayengbam S, Tuplin EWN, Sampsell K, Sharkey KA et al. · 2024
- 127Bañuls C, Rovira-Llopis S, Monzó N, Solá E, Viadel B, Víctor VM et al. · 2015
- 128Aslan Çİn NN, Açik M, Tertemİz OF, Aktan Ç, Akçali DT, Çakiroğlu FP et al. · 2024
- 129Keshteli AH, Valcheva R, Nickurak C, Park H, Mandal R, van Diepen K et al. · 2022
- 130Hull MA, McIntire DD, Atnip SD, Dreadin J, Nihira MA, Drewes PG et al. · 2011
- 131
- 132Kuo HH, Chen CC, Cho CC, Tsai CT, Chen SC, Hsu CL · 2026
- 133Amadieu C, Ahmed H, Leclercq S, Koistinen V, Leyrolle Q, Stärkel P et al. · 2025
- 134Camacho-Díaz BH, Arenas-Ocampo ML, Osorio-Díaz P, Jiménez-Aparicio AR, Alvarado-Jasso GM, Saavedra-Briones EV et al. · 2023
- 135Ghorbani A, Zarvandi M, Rakhshandeh H · 2019
- 136Vitale SG, Caruso S, Rapisarda AMC, Cianci S, Cianci A · 2018
- 137Ojetti V, Saviano A, Rizzi A, Tartaglione L, Di Leo M, Quaranta G et al. · 2026
- 138Brandt A, Yergaliyev T, Halibasic E, Cyba A, Jaeger JW, Gong R et al. · 2025
- 139Hoffmann Sardá FA, Giuntini EB, Oliveira A, Souza GS, Prado SBR, Taddei CR et al. · 2025
- 140Wierzbicka A, Khaidakov B, Zakerska-Banaszak O, Andrzejewska P, Baturo A, Kowalczyk P et al. · 2025
- 141Bărboi OB, Chirilă I, Ciortescu I, Anton C, Drug VL · 2022
- 142Ghalandari H, Kamalpour M, Alimadadi A, Nasrollahzadeh J · 2018
- 143de Bock M, Derraik JG, Brennan CM, Biggs JB, Smith GC, Cameron-Smith D et al. · 2012
- 144Flannery J, Raulerson A · 2000
- 145An Increase in Mediterranean Dietary Score, Through SunGold® Kiwifruit, Potentially Improves Mental Wellbeing· 2021
- 146Pucciani F, Raggioli M, Ringressi MN · 2011
- 147Li L, Zhao J, Wang J, Xiong Q, Lin X, Guo X et al. · 2024
- 148Sanabria-Véaz MG, Holthaus TA, Oleksiak M, Revilla D, Alvarado DA, Pérez-Tamayo M et al. · 2026
- 149de Andrade LS, Sardá FAH, Pereira NBF, Teixeira RR, Rodrigues SD, de Lima JD et al. · 2021
- 150Hamzah N, Mohamed HJJ, Vanoh D, Mohamed WMIW, Ismail D, Ali MKM et al. · 2026
- 151Wolever TM, Jenkins DJ, Mueller S, Patten R, Relle LK, Boctor D et al. · 1994
- 152Farsi DN, Cotillard A, Wilson B, So D, Gibson PS, Slater R et al. · 2026
- 153Stougaard EB, Tougaard NH, Sivalingam S, Hansen CS, Størling J, Hansen TW et al. · 2024
- 154Hartmann AM, D'Urso M, Dell'Oro M, Koppold DA, Steckhan N, Michalsen A et al. · 2023
- 155Escobar JS, Corrales-Agudelo V, Ortega-Sierra OL, Villota-Salazar NA, Rivera DA, Pulgarín-Zapata IC et al. · 2026
- 156Takahashi H, Fujii T, Yamada C, Kondo N, Kuramitsu K, Funasaka K et al. · 2025
- 157Suppakitjanusant P, Wang Y, Sivapiromrat AK, Hu C, Binongo J, Hunt WR et al. · 2024
- 158Williams CJ, Torquati L, Li Z, Lea RA, Croci I, Keating E et al. · 2022
- 159Abutair AS, Naser IA, Hamed AT · 2016
- 160Puhlmann ML, Wegh CAM, van der Zalm SCC, Dam V, Doolan A, Meyer D et al. · 2025
- 161Besora-Moreno M, Jiménez-Ten Hoevel C, Queral J, Bernal G, Pérez-Merino L, Puzo J et al. · 2026
- 162Kamalpour M, Ghalandari H, Nasrollahzadeh J · 2018
- 163Holmbäck U, Grudén S, Kuusk S, Litorp H, Englund J, Söderhäll A et al. · 2026
- 164Agrawal AR, Tandon M, Sharma PL · 2007
- 165Chen S, Peng D, Shan Y, Liu F, Du R, Bao Y et al. · 2024
- 166Sbarigia C, Ritieni C, Annibale B, Carabotti M · 2026
- 167Wang L, Liang C, Yu J, Zhang Y, Li H, Hu Y et al. · 2026
- 168Akçalı Ç, Uçar A, Atay K · 2025
- 169Drabińska N, Krupa-Kozak U, Jarocka-Cyrta E · 2020
- 170Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML · 2007
- 171Pasman WJ, Westerterp-Plantenga MS, Saris WH · 1997
- 172Calikoglu F, Barbaros U, Uzum AK, Tutuncu Y, Satman I · 2021
- 173Reid JESJ, Alhasani AT, MacCalman T, Amor D, Aliyu AI, Modasia AA et al. · 2026
- 174Kim KN, Kang MS, Joo NS, Lee HR, Jung S, Ju S et al. · 2025
- 175Mohamed M, Zagury RL, Bhaskaran K, Neutel J, Mohd Yusof BN, Mooney L et al. · 2023
- 176Karakan T, Ergun M, Dogan I, Cindoruk M, Unal S · 2007
- 177Birkeland E, Bamigbetan WA, Molven KD, Thorsby PM, Gulseth HL, Aas AM et al. · 2025
- 178Gogokhia L, Tran N, Grier A, Nagayama M, Xiang G, Funez-dePagnier G et al. · 2025
- 179Yan R, Devine A, Lo J, Marlow E, Dunican IC, Kunaratnam K et al. · 2026
- 180So D, Yao CK, Ardalan ZS, Thwaites PA, Kalantar-Zadeh K, Gibson PR et al. · 2022
- 181
- 182Davidson MH, Dugan LD, Burns JH, Sugimoto D, Story K, Drennan K · 1996
- 183He Y, Schofield J, Mahling P, Mendonza AE, Hinder M · 2020
- 184Pajk K, Bremec N, Kuzmanovski A, Lindič J, Pajek J, Knap B · 2025
- 185Ma Q, Sun T, Liu Z, Li D, Hu X · 2026
- 186Virgili J, Le Gall G, Vanhatalo A, Bond B, Vauzour D, Torquati L · 2025
- 187Rank MA, Barroso DL, Conn KA, Pecak M, Scandura M, Hirsch AH et al. · 2025
- 188Romo EZ, Hong BV, Agus JK, Jin Y, Kang JW, Zivkovic AM · 2025
- 189Villalva M, García-Díez E, López de Las Hazas MDC, Lo Iacono O, Vicente-Díez JI, García-Cabrera S et al. · 2025
- 190Batista AG, Zanzer YC, Marostica Junior MR, Östman EM · 2025
- 191Gunn D, Abbas Z, Harris HC, Major G, Hoad C, Gowland P et al. · 2022
- 192Alhasani AT, Modasia AA, Anodiyil M, Corsetti M, Aliyu AI, Crooks C et al. · 2025
- 193Haskey N, Ye J, Josephson J, Raman M, Ghosh S, Gibson DL · 2025
- 194Ancu O, Mackenzie RWA, Patterson M, Dsilva E, Yakubov GE, Haynes M et al. · 2025
- 195Ad Libitum Energy Intake Differences Between a Plant-Based, Low-Fat and an Animal-Based, Low-Carbohydrate Diet: An Inpatient Randomized Crossover StudyGallagher I, Boring J, Courville A, Guo J, Howard R, Milley L et al. · 2020
- 196Houghton MJ, Peiris DR, Sulaimani N, Visvanathan R, Nicolotti L, Cardoso BR · 2026
- 197Haas M, Brandl B, Neuhaus K, Wudy S, Kleigrewe K, Hauner H et al. · 2025
- 198Oliveira B, Falkenhain K, Little JP · 2022
- 199Pereira MTL, de Aquino AC, Porro C, Frota Gaban SV · 2026
- 200Lopez-Santamarina A, Cardelle-Cobas A, Mondragon ADC, Cepeda A, Rodriguez JA, Miranda JM · 2025
- 201Ater LJ, Plantz EK, Manning TD, Akers JD, Edwards ES, Kurti SP · 2025
- 202Al-Awadi AA, Grove JI, Bawden S, Vijay A, Valdes AM, Gowland P et al. · 2026
- 203Sasaki H, Matsumoto Y, Masutomi H, Ishihara K, Hirao K, Shibata S et al. · 2026
- 204Piperni E, Blanco-Míguez A, Mengoni C, Piccinno G, Punčochář M, Ren J et al. · 2026
- 205Bieglecka K, Kęszycka PK, Czerwińska J, Pastuszak K, Lange E, Owczarczyk-Saczonek A et al. · 2026
- 206Arreza AC, Wang J, Girard S, Foley KA, Baisley J, Recker S et al. · 2026
- 207Sánchez-Sánchez E, Díaz-Jiménez J, García-García A, Úbeda-Iglesias A, Muñoz-Tejada B, Martínez-Diegues J et al. · 2026
- 208Ifham Hanif M, Sholihah MM · 2025
- 209Mayengbam S, Raman M, Parnell JA, Eksteen B, Lambert JE, Eller LK et al. · 2025
- 210Kirschner SK, Engelen MP, Haas P, Bischoff SC, Deutz NE · 2025
- 211Chen XS, Liu HZ, Huang F, Meng J, Fang JX, Han Y et al. · 2025
- 212Koller KR, Wilson AS, Eberhart BL, Day GM, Lee FR, Perez MR et al. · 2025
- 213Armet AM, Li F, Deehan EC, Nikolaeva DD, Delannoy-Bruno O, Siegwald L et al. · 2025
- 214Pugh JE, Petropoulou K, Vasconcelos JC, Anjum A, Thom G, McCombie L et al. · 2024
- 215Mirgaloybayat S, Akbari Sene A, Jayervand F, Vazirian M, Mohazzab A, Kazerooni M · 2024
- 216Straus Farber R, Walker EL, Diallo F, Onomichi K, Riley C, Zhang L et al. · 2024
- 217Enhancing gut microbiota and microbial function with inulin supplementation in children with obesityVisuthranukul C, Sriswasdi S, Tepaamorndech S, Chamni S, Leelahavanichkul A, Joyjinda Y et al. · 2024
- 218Gearry R, Fukudo S, Barbara G, Kuhn-Sherlock B, Ansell J, Blatchford P et al. · 2023
- 219Menon J, Thapa BR, Kumari R, Puttaiah Kadyada S, Rana S, Lal SB · 2023
- 220Mathers JC, Elliott F, Macrae F, Mecklin JP, Möslein G, McRonald FE et al. · 2022
- 221Beyond “Counting Macros”: Are Common Fad Diets Nutritionally Adequate? An Examination of Their Micronutrient ContentMalik N, Tonstad S, Haddad E · 2020
- 222Koutsos A, Riccadonna S, Ulaszewska MM, Franceschi P, Trošt K, Galvin A et al. · 2020
- 223Major G, Murray K, Singh G, Nowak A, Hoad CL, Marciani L et al. · 2018
- 224Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S et al. · 2009
- 225Jiménez JP, Serrano J, Tabernero M, Arranz S, Díaz-Rubio ME, García-Diz L et al. · 2008
- 226Van Rosendaal GM, Shaffer EA, Edwards AL, Brant R · 2004
- 227Bouchoucha M, Faye A, Savarieau B, Arsac M · 2004
- 228Four-week supplementation with a natural dietary compound produces favorable changes in body compositionHoeger WW, Harris C, Long EM, Hopkins DR · 1998
- 229So D, Yao CK, Gill PA, Thwaites PA, Ardalan ZS, McSweeney CS et al. · 2023
- 230Yang C, Liu S, Li H, Bai X, Shan S, Gao P et al. · 2021
- 231Saraiya VM, Fung TT, Pitts SBJ, Wu Q, Berkowitz SA, Skinner HG et al. · 2026
- 232Sripongpun P, Lertpipopmetha K, Chamroonkul N, Kongkamol C · 2021
- 233Holte SS, Avaliani N, Hoff G, Kazaryan AM, Jaioun K, Lauzikas G et al. · 2025
Every statement on this page carries its evidence tier — proven, plausible or hypothesis — and leads to the original work. The decision in the individual case rests with the practitioner; we provide the connections.